학술논문
Evaluation of patients treated by telemedicine in the beginning of the COVID-19 pandemic in São Paulo, Brazil: A non-randomized clinical trial preliminary study.
Document Type
Academic Journal
Author
Chechter M; Centro Médico Mazzei - LaBriut, São Paulo, Brazil.; Dutra da Silva GM; Centro Médico Mazzei - LaBriut, São Paulo, Brazil.; E Costa RAP; Sociedade Brasileira de Valorização das Sociedades Médicas-SOBEMED, São Paulo, Brazil.; Miklos TG; Department of Obstetrics and Gynecology - Santa Casa of Sao Paulo Medical School, Sao Paulo (FCMSCSP), Brazil.; Antonio da Silva N; Federal University of Goias, Medical School, Department of Medical Clinic, Goiania, Brazil.; Lorber G; Laboratory DASA, São Paulo, Brazil.; Vasconcellos Mota NR; Centro Médico Mazzei - LaBriut, São Paulo, Brazil.; Dos Santos Cortada AP; Clinical Research Center of AACD, São Paulo, Brazil.; de Nazare Lima da Cruz L; Centro Médico Mazzei - LaBriut, São Paulo, Brazil.; de Melo PMP; Departamento de Neurocirurgia, Hospital Militar de Area de São Paulo, Brazil.; de Souza BC; Departamento de Ciencias, Universidade Federal de Pernambuco, Recife, Brazil.; Emmerich FG; Federal University of Espirito Santo, Vitoria, Brazil.; de Andrade Zanotto PM; Laboratory of Molecular Evolution and Bioinformatics (LEMB), Department of Microbiology, Institute of Biomedical Sciences (ICB-II), University of Sao Paulo, Sao Paulo, Brazil.; Aaron Scheinberg M; Hospital Israelita Albert Einstein, São Paulo, Brazil.
Source
Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101672560 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2405-8440 (Print) Linking ISSN: 24058440 NLM ISO Abbreviation: Heliyon Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2405-8440
Abstract
We performed a pilot open-label, non-randomized controlled clinical trial in a clinic in São Paulo, Brazil in the beginning of the COVID-19 pandemic. "This medical pilot project was carried out during the pandemic of a new and unknown agent. It was necessary to find a new and safe therapeutic approach for pathogens with high potential for severity and contamination. The repositioning of safe and accessible pre-existing and approved medications and the telemedicine approach improved treated covid patients' symptoms and reduced the risk of disease transmission. The emergency application of a new medical technology was the major limitation of the study. This innovative care model is a low-cost safe strategy, and we understand that applicability can be expanded to other regions in emergency situations." The 187 patients of the study (mean age of 37.6 ± 15,6 years) were divided into four groups: (1) asymptomatic, (2) mild symptoms, (3) moderate symptoms and (4) severe symptoms and were followed up for five days. A drug intervention was performed in group 3 and the patients of Group 4 were oriented to seek hospital care. Of all the patients, 23.0% were asymptomatic, 29.4% reported mild symptoms, 43.9% moderate symptoms and 3.7% severe symptoms. Three patients were hospitalized and discharged after recovery. Our results indicate that the use of telemedicine with diagnosis and drug treatment is a safe and effective strategy to reduce overload of health services and the exposure of healthcare providers and the population. The patients that initiated the treatment in the early stages of the disease presented satisfactory clinical response, reducing the need of face-to-face consultations and hospitalizations. The patients who followed the protocol treatment for COVID-19 with hydroxychloroquine and azithromycin for five days presented statistically significant improvement of clinical symptoms when compared to moderate patients who opted for not following the protocol (p < 0.05) and to all no treatment patients (p < 0.001).
Competing Interests: The authors declare no conflict of interest.
(© 2023 The Authors.)
Competing Interests: The authors declare no conflict of interest.
(© 2023 The Authors.)